Therapeutically, HCC cell membrane-coated nanoparticles carrying sorafenib and hsa_piR_016975 inhibitor could accurately target HCC cells by activating Maspin/GPX4-mediated ferroptosis and thus increase the sensitivity of HCC cells to sorafenib (Fig. 10B). Here, GPX4 is linked to hepatocellular carcinoma.